<DOC>
	<DOCNO>NCT02279667</DOCNO>
	<brief_summary>Single centre , open-label , randomised , three-way crossover study 18 healthy subject ( 9 male 9 female ) . The study consist three consecutive single-dose treatment period separate washout period 7 day . On treatment period , volunteer receive single dose BIA 2-093 800 mg , orally .</brief_summary>
	<brief_title>Single-dose Pharmacokinetics Relative Bioavailability Oral Suspension Two Tablet Formulations BIA 2-093</brief_title>
	<detailed_description>Sample size ( plan analyze ) : It plan least 16 healthy subject complete evaluable . Taking account potential occurrence dropout , two additional subject recruit enter study . Therefore , total 18 subject enrol . Diagnosis main selection criterion : Healthy male female volunteer age 18 45 year , body mass index 19 28 kg/m2 , non-smokers smoke less 10 cigarette equivalent per day .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 28 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign 12lead ECG screening . Subjects clinical laboratory test clinically acceptable screening . Subjects negative HBsAg , antiHCV Ab HIV1 HIV2 Ab test screen . Subjects negative alcohol drug abuse screen . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : doublebarrier , intrauterine device abstinence . ( If female ) She negative pregnancy test screen admission study period . Subjects conform inclusion criterion , Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects significant infection know inflammatory process screen and/or first admission . Subjects acute gastrointestinal symptom time screen and/or first admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use medicine within 2 week admission first period . Subjects participate clinical trial within 3 month prior screen . Subjects previously receive BIA 2093 . Subjects donate and/or receive blood blood product within previous 3 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects communicate reliably investigation team . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>